|
2024
|
Invention
|
Therapeutic compounds.
The present embodiments relate to substituted heterocyclic derivative the... |
|
2023
|
Invention
|
Bromodomain inhibitors.
The present invention relates to substituted heterocyclic derivative com... |
|
|
Invention
|
Bromodomain inhibitor.
Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5... |
|
|
Invention
|
Histone demethylase inhibitors.
The present invention relates generally to compositions and meth... |
|
2022
|
Invention
|
Process for the preparation of bromodomain inhibitor.
The present invention provides processes o... |
|
|
Invention
|
Bet inhibitor for treating glioblastoma. The present application relates generally to methods for... |
|
|
Invention
|
Methods of treating glioblastoma. The present application relates generally to methods for treati... |
|
|
Invention
|
Methods of treating glioblastoma.
The present application relates generally to methods for treat... |
|
|
Invention
|
Histone demethylase inhibitors. The present invention relates generally to compositions and metho... |
|
|
Invention
|
Bromodomain (bet) inhibitor for use in treating prostate cancer. The present application relates ... |
|
2021
|
Invention
|
Inhibitors of lysine specific demethylase-1. The present invention relates generally to compositi... |
|
|
Invention
|
Methods of treating prostate cancer.
The present application relates generally to methods for tr... |
|
|
Invention
|
Methods of treating prostate cancer. The present application relates generally to methods for tre... |
|
|
Invention
|
Histone demethylase inhibitors. The present disclosure relates generally to compositions and meth... |
|
|
Invention
|
Therapeutic compounds. The present embodiments relate to substituted heterocyclic derivative ther... |
|
|
Invention
|
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc.
The present... |
|
|
Invention
|
Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc. The present ... |
|
2020
|
Invention
|
Bromodomain inhibitors. The present invention relates to substituted heterocyclic derivative comp... |
|
|
Invention
|
Histone demethylase inhibitors. The present embodiments provide for substituted triazolylpyridine... |
|
|
Invention
|
Bromodomain and extra-terminal protein inhibitor combination therapy. The present disclosure rela... |
|
|
Invention
|
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for trea... |
|
|
Invention
|
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas. Methods are pro... |
|
|
Invention
|
Bromodomain inhibitor. Described herein is the bromodomain inhibitor 4-[2-(cyclopropylmethoxy)-5-... |
|
2019
|
Invention
|
Process for the preparation of bromodomain inhibitor. The present invention provides processes of... |
|
|
Invention
|
Compositions comprising an inhibitor of lysine specific demethylase-1. Described herein are amorp... |
|
|
Invention
|
Inhibitor of lysine specific demethylase-1. The present invention relates generally to compositio... |
|
2018
|
Invention
|
Kdm4 inhibitors.
The present disclosure relates generally to compounds and methods for inhibitin... |
